Failure to increase the in vivo immunosuppressive activity of antilymphocyte globulin by conjugation with melphalan

L BrentP Wood


An attempt was made to increase the in vivo immunosuppressive powers of antilymphocyte globulin (ALG) by conjugating it with malphalan (MEL), an alkylating agent, via an inert intermediate carrier (polyglutamic acid). Careful controls to distinguish between increased activity attributable to the conjugate per se, as opposed to synergy between the components of the complex, were included. Conjugation did not destroy the alkylating properties of the drug nor the cytotoxic activity of the antibody. The effect of MEL-ALG complexes on skin allograft survival in both inbred and outbred strains were appraised. In neither system did the immunosuppressive powers of the conjugate exceed those of ALG alone, regardless of the dose used. We conclude that alkylating drugs are not suitable for this particular purpose.


Apr 1, 1987·Immunology and Cell Biology·G A PieterszI F McKenzie

Related Concepts

Lymphocyte Immune Globulin, Anti-Thymocyte Globulin (Equine)
Immunologic Tumoricidal Activities
Graft Rejection
Therapeutic Immunosuppression
Mice, Inbred A
Mice, Inbred CBA
Transplantation, Autologous
Transplantation, Homologous

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.